Increasing demand for biotechnology products such as insulin, growth hormones, antibodies and therapeutics drives market growth. Recombinant DNA technology has enabled mass production of these biotech products. It has also facilitated development of new drugs for diseases like cancer and genetic disorders. Growing prevalence of chronic diseases globally also drives growth for recombinant DNA technology. Advancements in gene therapy and stem cell research have also augmented market growth.
Request a Sample Copy of the Report @ https://www.coherentmarketinsights.com/insight/request-sample/893
Market Trends
Growing adoption of gene therapy is a key trend driving market growth. Gene therapy involves modification of gene expression or altering genetic sequences. It holds potential to revolutionize treatment of various inherited disorders and cancer. Another trend gaining traction is increasing R&D investments by biotech companies. They develop novel biologic drugs for conditions with high unmet need.
Recombinant DNA Technology Market Report Coverage
|
Report Coverage |
Details |
|
Market Revenue in 2024 |
$172.94 billion |
|
Estimated Value by 2031 |
$327.63 billion |
|
Growth Rate |
Poised to grow at a CAGR of 9.6% |
|
Historical Data |
2019–2023 |
|
Forecast Period |
2024–2031 |
|
Forecast Units |
Value (USD Million/Billion) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
By Product Type, By Application, By End User |
|
Geographies Covered |
North America, Europe, Asia Pacific, and Rest of World |
|
Growth Drivers |
• Increasing Technological Advancements are Facilitating the Production of Novel Products • Growing Applications in Healthcare |
|
Restraints & Challenges |
• High Cost Associated with Clinical Trials • Strict Regulations and Ethical Concerns |
Market Opportunities
Recombinant protein drugs segment is expected to dominate recombinant DNA technology market. It is expected to hold the largest market share of 25% in 2024. This is owing to the increasing prevalence of chronic diseases and advanced product offerings from key players.
Immediate Delivery Available | Buy This Premium Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/893
The therapeutics application segment is anticipated to witness the fastest growth. It accounted for revenue of US$ 89.32 Bn in 2024. It is expected to exhibit a CAGR of 10.1% during the forecast period. Ongoing efforts to develop novel biologics for the treatment of cancer and neurodegenerative diseases supports growth of this segment.
Biotechnology and pharmaceutical companies is expected to dominate end user segment. This segment is expected to hold over 60% of the global market share in 2024. This is due to large R&D investments made by these companies in recombinant protein drug development.
North America is expected to remain the dominant regional market with a share of 40% in 2024. This is due to favourable regulatory environment and presence of major biotech players in the U.S. and Canada.
Key Market Takeaways
The global recombinant DNA technology market is anticipated to witness a CAGR of 9.6% during the forecast period 2024-2031. This is owing to the strong product pipeline and significant funding in biologics R&D.
On the basis of product type, recombinant protein drugs segment is expected to hold a dominant position. This is owing to increasing usage of protein therapeutic across various therapeutic areas.
On the basis of application, therapeutics segment is expected to hold the major share over the forecast period. This is due to robust adoption of gene therapy tools.
North America is expected to hold a dominant position over the forecast period. This is due to availability of advanced research infrastructure and presence of major biopharma firms.
Competitor Insights
- Thermo Fisher Scientific Inc
- Biogen Inc,
- Sanofi
- Pfizer, Inc.
- Amgen, Inc.
- Merck & Co., Inc.
- Profagen,
- Mansanto Company
- Greentech, Inc.
- Eli Lilly and Company
- Janseen Pharmaceutical Inc.
- GSK plc.
- Jiangsu Recbio Technology Co., Ltd.
Recent Developments
In January 2022, Jiangsu Recbio Technology Co., Ltd. developed recombinant COVID-19 vaccine ReCOV.
In January 2024, Core Biogenesis and Nucleus Biologics announced a collaboration. This collaboration aimed at manufacturing and distribution of cost-effective recombinant proteins.
Ask For Customization @ https://www.coherentmarketinsights.com/insight/request-customization/893
Detailed Segmentation-
By Product Type:
- Recombinant Protein Drugs
- Vaccines
- Genetically Modified Crops
- Cell and Gene Therapy
- Gene Editing
By Application:
- Therapeutics
- Agriculture
- Research
- Others
By End User:
- Biotechnology and Pharmaceutical Company
- Diagnostic Laboratories
- Academic and Government Laboratories
- Others
By Region:
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Find Most Trending Related Reports:
The global cell and gene therapy market is estimated to be valued at US$ 22.7 billion in 2023 and is expected to exhibit a CAGR of 28.7% during the forecast period (2023-2030).
The global biopharmaceuticals market was valued at US$ 371.26 Bn in 2022 and is forecast to reach a value of US$ 654.76 Bn by 2030 at a CAGR of 7.4% between 2023 and 2030
The global vaccine technologies market size is estimated to be valued at US$ 45.40 Bn in 2023 and is expected to reach US$ 91.50 Bn by 2030, growing at a compound annual growth rate (CAGR) of 10.5% from 2023 to 2030
The global Red Biotechnology Market size is expected to reach US$ 1,513.22 Bn by 2030, from US$ 742.80 Bn in 2023, exhibiting a CAGR of 10.7% during the forecast period.
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: +1-650-918-5898
UK: +44-020-8133-4027
AUS: +61-2-4786-0457
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
